| Name | Title | Contact Details |
|---|
CCA Medical is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quantum Medical Imaging is a Ronkonkoma, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedaPhase is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.